ArticleCancers2019

Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer.

Jin-Sun Ryu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.